UNITED STATES SECURITIES AND EXCHANGE COMMISSION February 9, 2012

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Tekmira Pharmaceuticals Corporation

File No. 1-34949 - CF#26949

Tekmira Pharmaceuticals Corporation submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 20-F filed on June 3, 2011.

Based on representations by Tekmira Pharmaceuticals Corporation that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 4.1	Through	July 20, 2020
Exhibit 4.2	Through	July 20, 2020
Exhibit 4.3	Through	January 8, 2021
Exhibit 4.4	Through	May 30, 2020
Exhibit 4.5	Through	May 30, 2020
Exhibit 4.6	Through	July 20, 2016
Exhibit 4.7	Through	July 20, 2020
Exhibit 4.8	Through	January 2, 2021
Exhibit 4.16	Through	September 1, 2020
Exhibit 4.17	Through	September 1, 2020
Exhibit 4.18	Through	September 1, 2020
Exhibit 4.19	Through	September 1, 2020
Exhibit 4.20	Through	September 1, 2020
Exhibit 4.21	Through	July 20, 2020

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Daniel Greenspan Legal Branch Chief